Answers are grounded in this paper and cite their sources.
CI-920 (PD 110,161) and two analogues (PD 113,270 and PD 113,271) are novel antitumor compounds produced by a new actinomycete characterized as Streptomyces pulveraceus subsp. fostreus ATCC 31906. The antitumor compounds are predominantly produced during the stationary (idiophase) growth phase of the organism. CI-920 is active versus the murine P388 lymphocytic and L1210 lymphoid leukemia with T/C values of 246 and 207, respectively. This compound has no significant antimicrobial activity.
No takes yet. Share an insight, caveat, or question.
Tunac et al. (1983) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: